Acadian Asset Management
CLDX icon

Acadian Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Acadian Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,591
Closed -$156K – 1709
2024
Q3 		$156K Buy
+4,591
New +$175K ﹤0.01% 1450
2020
Q3 		– Sell
-228,015
Closed -$2.96M – 2192
2020
Q2 		$2.96M Sell
228,015
-70,634
-24% -$313K 0.01% 623
2020
Q1 		$496K Buy
298,649
+50,583
+20% +$114K ﹤0.01% 962
2019
Q4 		$553K Sell
248,066
-8,242
-3% -$19.1K ﹤0.01% 1046
2019
Q3 		$547K Sell
256,308
-11,249
-4% -$26K ﹤0.01% 1062
2019
Q2 		$718K Buy
267,557
+120,519
+82% +$409K ﹤0.01% 899
2019
Q1 		$723K Buy
147,038
+55,480
+61% +$292K ﹤0.01% 1007
2018
Q4 		$272K Buy
91,558
+19,152
+26% +$94.1K ﹤0.01% 1051
2018
Q3 		$490K Sell
72,406
-4,786
-6% -$33.5K ﹤0.01% 884
2018
Q2 		$583K Buy
77,192
+61,058
+378% +$816K ﹤0.01% 859
2018
Q1 		$563K Buy
+16,134
New +$625K ﹤0.01% 833

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management's CLDX Position: Q4 2024 in Review

Acadian Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 4,591 shares — an estimated $156K sold.

Acadian Asset Management first reported a position in CLDX in Q1 2018 and held it in 11 quarters. The position peaked at $2.96M in Q2 2020. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Acadian Asset Management reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 4,591 Celldex Therapeutics shares in Q4 2024, an estimated $156K.
  • Acadian Asset Management first reported a position in Celldex Therapeutics in Q1 2018 and held it in 11 quarters.
  • Acadian Asset Management's Celldex Therapeutics position peaked at $2.96M in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.